Statins

Clinical Lipidology: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2009, Pages 253-280

  McKenney, James M ^a   Ganz, Peter ^b,c   Wiggins, Barbara S ^d   Saseen, Joseph S ^e  

^a National Clinical Research Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958129859     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605469-6.50026-3     Document Type: Chapter

References (197)

1. Endo A The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992, 33:1569-1582.
2. Crestor Prescribing Information. AstraZeneca Pharmaceuticals, Wilmingon, DE. January, 2007.
3. Lescol Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, NJ. April 2006.
4. Lipitor Prescribing Information. Pfizer, NY, NY. March 2007.
5. Mevacor Prescribing Information. Merck & Co, Whitehouse Station, NJ. November, 2005.
6. Pravachol Prescribing Information. Bristol-Myers Squibb, Princeton, NJ. August, 2005.
7. Zocor Prescribing Information. Merck & Co, Whitehouse Station, NJ. August, 2005.
8. Istvan ES, Deisenhofer J Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001, 292:1160-1164.
9. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001, 87(suppl):28B-32B.
10. Holdgate GA, Ward WH, McTaggart F Molecular mechanisms for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003, 31:528-531.
11. Brown MS, Goldstein JL A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
12. Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987, 80:1692-1697.
13. Arad Y, Ramakrishnan R, Ginsberg HN Lovastatin therapy reduces low-density lipoprotein apoB levels in subjects with combined hyperlipdemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 1990, 31:567-582.
14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
16. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
17. Grundy SM Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 2002, 90(suppl):11i-21i.
18. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
19. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946-955.
20. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
21. Sukhova GK, Williams JK, Libby P Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002, 22:1452-1458.
22. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447-1452.
23. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
24. Correia LC, Sposito AC, Lima JC, et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2003, 92:298-301.
25. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001, 88:1306-1307.
26. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415.
27. van Heek M, Farley C, Compton DS, et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 2003, 138:1459-1464.
28. Ballantyne CM, Andrews TC, Hsia JA, et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001, 88:265-269.
29. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001, 104:376-379.
30. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
31. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: Clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006, 27:1182-1190.
32. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004, 95:217-223.
33. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
34. Davignon J The cardioprotective effects of statins. Curr Atheroscler Rep 2004, 6:27-35.
35. Rikitake Y, Liao JK Rho GTPases, statins, and nitric oxide. Circ Res 2005, 97:1232-1235.
36. Laufs U, Liao JK Targeting Rho in cardiovascular disease. Circ Res 2000, 87:526-528.
37. Shimokawa H, Takeshita A Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005, 25:1767-1775.
38. Takai Y, Sasaki T, Matozaki T Small GTP-binding proteins. Physiol Rev 2001, 81:153-208.
39. Fukata Y, Amano M, Kaibuchi K Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001, 22:32-39.
40. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996, 15:1885-1893.
41. Leung T, Manser E, Tan L, Lim L A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995, 270:29051-29054.
42. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996, 15:2208-2216.
43. Riento K, Ridley AJ ROCKS: Multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003, 4:446-456.
44. Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 2000, 106:15-24.
45. Takemoto M, Liao JK Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
46. Wolfrum S, Jensen KS, Liao JK Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003, 23:729-736.
47. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002, 22:8467-8477.
48. Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106:57-62.
49. Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004, 24:1842-1847.
50. Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002, 39:245-350.
51. Kandabashi T, Shimokawa H, Mukai Y, et al. Involvement of Rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 2002, 22:243-248.
52. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38:100-104.
53. Miyata K, Shimokawa H, Kandabashi T, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 2000, 20:2351-2358.
54. Lefer DJ, Scalia R, Jones SP, et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 2001, 15:1454-1456.
55. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998, 95:8880-8885.
56. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101:2711-2719.
57. Bourcier T, Libby P HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:556-562.
58. Essig M, Nguyen G, Prie D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998, 83:683-690.
59. Eto M, Kozai T, Cosentino F, et al. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002, 105:1756-1759.
60. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001, 21:1896-1901.
61. Lefer AM, Scalia R, Lefer DJ Vascular effects of HMG-CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. Cardiovasc Res 2001, 49:281-287.
62. Laufs U, Marra D, Node K, Liao JK 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999, 274:21926-21931.
63. Slotta JE, Braun OO, Menger MD, Thorlacius H Fasudil, a Rho-kinase inhibitor, inhibits leukocyte adhesion in inflamed large blood vessels in vivo. Inflamm Res 2006, 55:364-367.
64. Morishige K, Shimokawa H, Eto Y, et al. Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 2001, 21:548-554.
65. Eto Y, Shimokawa H, Hiroki J, et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol 2000, 278:H1744-H1750.
66. Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 2001, 51:169-177.
67. Matsumoto Y, Uwatoku T, Oi K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004, 24:181-186.
68. Kandabashi T, Shimokawa H, Miyata K, et al. Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscler Thromb Vasc Biol 2003, 23:2209-2214.
69. Hattori T, Shimokawa H, Higashi M, et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004, 94:46-52.
70. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001, 15:1062-1064.
71. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109:2234-2239.
72. Shibuya M, Asano T, Sasaki Y Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm. Acta Neurochir Suppl 2001, 77:201-204.
73. Nagata K, Kondoh Y, Satoh Y, et al. Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. Clin Neuropharmacol 1993, 16:501-510.
74. Masaoka H, Takasato Y, Nojiri T, et al. Clinical effect of Fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage. Acta Neurochir Suppl 2001, 77:209-211.
75. Tanaka Y, Masuzawa T, Saito M, et al. Combined administration of Fasudil hydrochloride and nitroglycerin for treatment of cerebral vasospasm. Acta Neurochir Suppl 2001, 77:205-207.
76. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002, 105:1545-1547.
77. Inokuchi K, Ito A, Fukumoto Y, et al. Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol 2004, 44:275-277.
78. Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003, 41:15-19.
79. Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001, 38:1307-1310.
80. Noma K, Higashi Y, Jitsuiki D, et al. Smoking activates rho-kinase in smooth muscle cells of forearm vasculature in humans. Hypertension 2003, 41:1102-1105.
81. Noma K, Goto C, Nishioka K, et al. Smoking, endothelial function, and Rho-kinase in humans. Arterioscler Thromb Vasc Biol 2005, 25:2630-2635.
82. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: A multicenter study. J Cardiovasc Pharmacol 2002, 40:751-761.
83. Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: A double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005, 46:1803-1811.
84. Nohria A, Grunert ME, Rikitake Y, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006, 99:1426-1432.
85. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004-1010.
86. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005, 36:2251-2257.
87. Davidson MH, Robinson JG Lipid-lowering effects of statins: A comparative review. Expert Opin Pharmacother 2006, 7:1701-1714.
88. Shitara Y, Sugiyama Y Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutryl coenzyme A (HMG-CoA) reductase inhibitor: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
89. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301:1042-1051.
90. Neuvonen PJ, Niemi M, Backman JT Drug interactions with lipid-lowering drugs: Mechanism and clinical relevance. Clin Pharmacol Ther 2006, 80:565-581.
91. Lilja JJ, Neuvonen M, Neuvonen PJ Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004, 58:56-60.
92. Kantola T, Kivisto KT, Neuonen PJ Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998, 63:397-402.
93. Lilja JJ, Kivisto KT, Neuvonen PJ Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999, 66:118-127.
94. Lilja JJ, Kivisto KT, Neuvonen PJ Duration of effect of grapefruit juice on the pharmacokinetics of the CYP 3A4 substrate simvastatin. Clin Pharmacol Ther 2000, 68:384-390.
95. Fuhr U, Frummert AL The fate of naringin in humans: A key to grapefruit juice-drug interactions. Clin Pharmacol Ther 1995, 58:365-373.
96. Stone NJ Stopping statins. Circulation 2004, 110:2280-2282.
97. Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000, 56:225-229.
98. Shitara Y, Itoh T, Sato H, et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A. J Pharmacol Exp Ther 2003, 304:610-616.
99. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
100. Bellosta S, Paoletti R, Corsini A Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(suppl III):50-57.
101. Shitara Y, Hirano M, Santo H, Sugiyama Y Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (ASTP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004, 311:228-236.
102. The FIELD Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2006, 366:1849-1861.
103. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003, 92:152-160.
104. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: Results from the STELLAR trial. Curr Med Res Opin 2003, 19:689-698.
105. Stein EA, Lane M, Laskarzewski P Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998, 81(suppl 4A):66B-69B.
106. Rosenson R, Otvos JD, Freedman DS Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial. Am J Cardiol 2002, 90:89-94.
107. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 2001, 88:270-274.
108. Sacks FM, Alaupovic P, Moye LA Effect of pravastatin on apolipoprotein B and C-III in very low-density lipoproteins and low-density lipoproteins. Am J Cardiol 2002, 90:165-167.
109. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipidemia. Am J Cardiol 2002, 89:386-389.
110. Pedersen TR, Anders GO, Ole F, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460.
111. Geurin M, Egger P, Le Goff W, et al. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab 2002, 87:4991-5000.
112. Asztalos BF, Maulf FL, Dallal GE, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulation of high-density lipoprotein. Am J Cardiol 2007, 99:681-685.
113. Grundy SM, Cleeman JI, Meraz CNB, et al. Implications of recent clinical trials for the National Cholesterol Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
114. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
115. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
116. Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
117. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
118. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER); A randomised controlled trial. Lancet 2002, 360:1623-1630.
119. Colhoun HM, Betteridge DJ, Durrington PN, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005, 48:2482-2485.
120. Neil HA, DeMicco DA, Luo DJ, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization. Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006, 29:2378-2384.
121. Sever PS, Poulter NR, Dahlof B, et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). Am J Cardiol 2005, 96(suppl):39F-44F.
122. ALLHAT officers and coordinators for the ALLHAT collaborative research group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
123. Gibson DM, Bron NJ, Richens A, et al. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 1996, 36:242-246.
124. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007, 115:1948-1967.
125. Kasiske BL, Wanner C, O'Neill WC An assessment of statin safety by nephrologists. Am J Cardiol 2006, 97(suppl):82C-85C.
126. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
127. Cohen DE, Anania FA, Chalasani N An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:77C-81C.
128. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287-1292.
129. Vuppalanchi R, Teal E, Chalasani N Patients with elevated baseline liver enzymes do not have a higher frequency of hepatoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62-65.
130. Kiyici M, Gulten M, Gurel M, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003, 17:713-718.
131. Rallidis LS, Drakoulis CK, Parasi AS Pravastatin in patients with nonalcoholic steatohepatitis: Results of a pilot study. Atherosclerosis 2004, 174:193-196.
132. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 2004, 57:728-734.
133. Tonelli M, Moyé L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003, 14:1605-1613.
134. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52-60.
135. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: The effects of statins. Am J Kidney Dis 2002, 40:638-643.
136. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002, 61:297-304.
137. Vaughan CJ, Delanty N Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999, 30:1673-1969.
138. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council. Circulation 2006, 113:e873-e923.
139. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Circulation 2006, 113:409-449.
140. National Cholesterol Education Program Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002, 106:3143-3421.
141. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
142. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008, 70:2364-2370.
143. Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
144. Pedersen TR, Kjekshus J, Pyörälä K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998, 81:333-335.
145. Mohler ER, Hiatt WR, Creager MA, et al. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108:1481-1486.
146. Jadhav SB, Jain GK Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol 2006, 58:3-18.
147. Wang PS, Solomon DH, Mogun H, Avorn J HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000, 283:3211-3216.
148. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205-3210.
149. Van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001, 285:1850-1855.
150. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study; secondary analysis of a randomized controlled trial. Lancet 2001, 357:509-512.
151. McClung MR, Kiel DP, Lindsay RS, et al: A 12-month, dose response study of atorvastatin effects on bone in postmenopausal women. Poster presented to the American Society of Nephrology, November 17, 2006.
152. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001, 322:1447-1451.
153. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17:14-20.
154. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002, 59:223-227.
155. Wolozin B, Kellman W, Rousseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443.
156. Sparks DL, Scheff SW, Hunsaker JC, et al. Induction of Alzheimer-like β amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994, 126:88-94.
157. Sparks DL Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 1996, 17:291-299.
158. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005, 62:753-757.
159. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
160. Iso H, Jacobs DR Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989, 320:904-910.
161. Yano K, Reed DM, MacLean DJ Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989, 20:1460-1465.
162. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low, low-density lipoprotein with intense statin therapy. A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005, 46:1411-1416.
163. Schonfeld G Familial hypobetalipoproteinemia: A review. J Lipid Res 2003, 44:878-883.
164. Welty FK, Mittleman MA, Wilson PWF, et al. Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Circulation 1997, 95:825-830.
165. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy. A systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
166. Law M, Rudnicka AR Statin safety: A systemic review. Am J Cardiol 2006, 97(suppl):52C-60C.
167. US Food and Drug Administration, Center for Drug Evaluation and Research: Statins and hepatotoxicity. (US Food and Drug Administration Web site) Available at: . Accessed August 15, 2005. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3622b2b_safety_review.pdf .
168. Tolman KG The liver and lovastatin. Am J Cardiol 2002, 89:1374-1380.
169. McKenney JM, Davidson MH, Jacobson TA, Guyton JR Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97(suppl):89C-94C.
170. Davidson MH, Clark JA, Glass LM, Kanumalla A Statin safety: an appraisal from the Adverse Event Reporting System. Am J Cardiol 2006, 97(suppl):32C-43C.
171. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006, 97(suppl):61C-68C.
172. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
173. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
174. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
175. Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005, 25:2560-2566.
176. The SEARCH Collaborative Group SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med 2008, 359:789-799.
177. Paiva H, Thelen KM, Coster V, et al. High dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin
178. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2:483-491.
179. Caso G, Kelly P, McNurlan MA, Lawson WE Effect of coenzyme Q10 on myopathic symptoms in patients treated with statin. Am J Cardiol 2007, 99:1409-1412.
180. Marcoff L, Thompson PD The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
181. Rosenson RS Current overview of statin-induced myopathy. Am J Med 2004, 116:408-416.
182. Jacobson TA Statin safety Lessons from New Drug Applications for marketed statins. Am J Cardiol 2006, 97(suppl):44C-51C.
183. Bottorff M, Hansten P Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med 2000, 160:2273-2280.
184. Sidaway JE, Davidson RG, McTaggart F Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004, 15:2258-2265.
185. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002, 105:2341-2346.
186. US Food and Drug Administration: FDA Public Health Advisory on Crestor (rosuvastatin). Center for Drug Evaluation and Research. (FDA Web site) Available at: . Accessed February 6, 2006. http://www.fda.gov/cder/drug/advisory/crestor_3_2005.htm.
187. Chong PH, Boskovich A, Stevkovic N, Bartt RE Statin-associated peripheral neuropathy: Review of the literature. Pharmacotherapy 2004, 24:1194-1203.
188. PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002, 360:1623-1630.
189. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
190. Bays H Statin safety: An overview and assessment of the data-2005. Am J Cardiol 2006, 97(suppl):6C-26C.
191. Saheki A, Terasaki T, Tamai I, Tsuji A In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994, 11:305-311.
192. Brass LM, Alberts MJ, Sparks L An assessment of statin safety by neurologists. Am J Cardiol 2006, 97(suppl):86C-88C.
193. Serruys PWJ, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 2002, 287:3215-3222.
194. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
195. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998, 279:1615-1622.
196. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
197. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial. JAMA 2005, 294:2437-2445.